002603 以岭药业
2024/09 - 九个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)4.83412.08523.62614.94114.450
总资产报酬率 ROA (%)3.3038.11816.15811.01611.854
投入资产回报率 ROIC (%)4.0069.83219.72213.30312.087

边际利润分析
销售毛利率 (%)53.39457.28263.77163.61564.493
营业利润率 (%)11.04617.24922.57715.51016.374
息税前利润/营业总收入 (%)10.96216.57822.34615.52916.176
净利润/营业总收入 (%)8.62613.02818.81313.26113.834

收益指标分析
经营活动净收益/利润总额(%)95.45894.947103.068100.217101.204
价值变动净收益/利润总额(%)5.8573.8770.414-1.4092.081
营业外收支净额/利润总额(%)-4.616-5.677-1.759-0.988-1.094

偿债能力分析
流动比率 (X)1.5701.4721.4961.8922.438
速动比率 (X)1.0770.9191.0791.3271.733
资产负债率 (%)30.86832.63633.11129.69922.354
带息债务/全部投入资本 (%)12.13414.73316.3569.743--
股东权益/带息债务 (%)692.631554.734495.085889.9091,802.472
股东权益/负债合计 (%)224.314206.624202.053236.627347.190
利息保障倍数 (X)27.19664.873140.59390.712-773.474

营运能力分析
应收账款周转天数 (天)109.84972.01247.93448.8120.000
存货周转天数 (天)200.205182.969146.462159.0760.000